TrialAnnals of the rheumatic diseases2014

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.

Daniel J Wallace et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.